Dr Nteliopoulos is a senior research associate who is managing the Circulating Biomarker Laboratory within the Division of Cancer of Imperial College London (ICL). The purpose of the laboratory is to assist ICL researchers working on solid tumours or/and haematological malignancies with a particular interest in the analysis of liquid biopsies. Dr Nteliopoulos is focusing on isolating and analysing single circulating tumour cells (CTCs) and cell-free circulating tumour DNA (ctDNA) from cancer patients' blood samples with a view to monitoring tumour-related changes, such as mutations at a single cell level.
Previously, he worked at the Centre for Haematology in a group led by Prof Jane Apperley interested in Chronic Myeloid Leukemia (CML). His research was focused on identifying molecular biomarkers (mutations, DNA methylation, gene expression), detectable at diagnosis of CML, that can predict patients associated with treatment failure to tyrosine kinase inhibitors therapy.
He has been awarded a PhD in Haematopoietic Stem/Progenitor Cells, an MRes in Cancer Informatics and an MSc in Molecular Medicine from Imperial College.
et al., 2022, Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma, Expert Review of Molecular Diagnostics, Vol:22, ISSN:1473-7159, Pages:253-264
et al., 2021, Circulating tumor DNA profiling from breast cancer screening through to metastatic disease, Jco Precision Oncology, Vol:5, ISSN:2473-4284, Pages:1768-1776
et al., 2021, Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients, Breast Cancer Research and Treatment, Vol:188, ISSN:0167-6806, Pages:465-176
et al., 2021, Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B, Oncogene, Vol:40, ISSN:0950-9232, Pages:2697-2710
et al., 2021, Genomic copy number profiling of single CTCs reveals clonal evolution in metastatic breast cancer and identifies actionable targets for informing treatment decisions., AMER ASSOC CANCER RESEARCH, ISSN:0008-5472